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ABSTRACT 
The newly synthesized compounds are being tested for in vitro anti-cancer activity. Method used for In Vitro testing is Sulforhodamine B assay 
also known SRB assay. Cell lines were prepared and homoginised and disassociated with the help of trypsin. Then trypsin was inactivated with 
fetal bovine serum. Then cell concentration was determined. Synthesised molecules where prepared in to four different dillutions and exposed 
to cell lines. The procedure was also compared with standard drug doxorubicin. All the cell medium was incubated 37 degrees centigrade in a 
humidified incubator with 5 percentage CO. The plates were stainned and fixed with trichloroacetic acid. Finally the plates were incubated in 
orbital shaker incubater and absorbance was measured in micro plate reader at 510nm. All compounds (1-30) showed similar anticancer 
activity of compounds (IA, IB, ID,IE,IF, IIB,IIC, IIIA, IVB, IVF, VA, VC, VD, VE.) were more potent when compared to the rest of the compounds 
synthesized. 
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INTRODUCTION 
Cancer is also called as malignancy disease where group of 
abnormal cells undergo cell division uncontrollable beyond 
regular methods. In broad term malignancy is an illness of 
cellular changes that results in uncontrolled cell division, 
sometimes it may be rapid cell division or cell grow or divide 
in a slow rate. Normal cell shall be divided by controlled 
signals which instruct cells to divide, differentiation or to 
die. Whereas malignant cells builds autonomy signals causes 
uncontrolled growth with proliferation.1-3 Sulfordamine B 
assay is an In Vivo model where an extrinsic method to 
estimate anti-tumour activity.4-5 it is the method which was 
developed in the year 1990.3 This Method majorly depends 
on the stoichiometric binding of SRB dye with proteins at 
mild acidic conditions which can be extracted by reverse 
basic canditions.6-7 The process is majorly categorised into 
four stages preparation of treatment, incubation of cells with 
treatment of choice, cell fixation and SRB staining, and 
absorbance measurement.8 
 
MATERIALS AND METHODS: 
96, 384 well clear flat-bottom polystyrene tissue-culture 
plates, 96 well PCR plates, 100mm tissue culture plates,15ml 
falcon tubes, 1.5ml eppendorf tubes, pipette tips, 
125microliter and 1250 microliter matrix pipette, human 
skin cancer cell line G361, culture medium, sterile and 
nonsterile reservoir, opti-MEM or serum free medium, 
phosphate buffer saline (PBS),2.5%w/v trypsin solution, 
fatal bovine serum, tryptan blue, trichloroacetic acid, 
sulforhodamine B sodium salt in 1%v/v acetic acid, acetic 
acid, 10mM unbuffered tris base solution, Lipofectamine 
RNA imax, mirvana miRNA mimics, mi RNA precursor 
molecules – negative control.9 
Testing method: Sulforhodamine B assay. 
Sample solution preparation: 
Synthesized compounds were prepared by in the 
concentration of 50 microliter and other dilution and added 
96-well plates at a triplicate final volume was made up to 
100 microliter with DMSO. 
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Table 01 List of synthesized molecules and their concentration 
S.NO SAMPLE ID  DILUTION-1 DILUTION-2 DILUTION-3 DILUTION-4 
1 PG-1A 10-7 10-6 10-5 10-4 
2 PG-1B 10-7 10-6 10-5 10-4 
3 PG-1C 10-7 10-6 10-5 10-4 
4 PG-1D 10-7 10-6 10-5 10-4 
5 PG-1E 10-7 10-6 10-5 10-4 
6 PG-1F 10-7 10-6 10-5 10-4 
7 RS-1A 10-7 10-6 10-5 10-4 
8 RS-1B 10-7 10-6 10-5 10-4 
9 RS-1C 10-7 10-6 10-5 10-4 
10 RS -1D 10-7 10-6 10-5 10-4 
11 RS -1E 10-7 10-6 10-5 10-4 
12 RS -1F 10-7 10-6 10-5 10-4 
13 OR-1A 10-7 10-6 10-5 10-4 
14 OR-1B 10-7 10-6 10-5 10-4 
15 OR-1C 10-7 10-6 10-5 10-4 
16 OR-1D 10-7 10-6 10-5 10-4 
17 OR -1E 10-7 10-6 10-5 10-4 
18 OR -1F 10-7 10-6 10-5 10-4 
19 HQ-1A 10-7 10-6 10-5 10-4 
20 HQ-1B 10-7 10-6 10-5 10-4 
21 HQ-1C 10-7 10-6 10-5 10-4 
22 HQ-1D 10-7 10-6 10-5 10-4 
23 HQ -1E 10-7 10-6 10-5 10-4 
24 HQ -1F 10-7 10-6 10-5 10-4 
25 HL-1A 10-7 10-6 10-5 10-4 
26 HL-1B 10-7 10-6 10-5 10-4 
27 HL-1C 10-7 10-6 10-5 10-4 
28 HL-1D 10-7 10-6 10-5 10-4 
29 HL -1E 10-7 10-6 10-5 10-4 
30 HL -1F 10-7 10-6 10-5 10-4 
31 ADR 10-7 10-6 10-5 10-4 
 
Cell line preparation: 
Trypsinization: Cell line monolayer’s are washed with 
sterilized phosphate buffer saline (PBS). PBS was removed 
from the medium and then added 1ml of 0.25 %( w/v) 
trypsin to evenly cover the cell line surface. Then incubate 
the cell medium at 37oC for 5 min until cells start to 
dissociate from its surface. Trypsin was inactivated with 10 
volumes of culture medium containing (fetal bovine serum) 
FBS by mixing up and down until single homogenous single 
cell suspension. Single cell suspension was transferred to a 
sterile falcon tube.10 
Determination of cell concentration. 
Single cell suspension was filled in a falcon tube and 0.4% 
(w/v) tryptan blue solution in a ratio  1:1 and then cell 
suspension was measured for cell concentration in 
hematocytometer chamber under a microscope to determine 
cell viability prior cell seeding and verified for cell health. 
Cell concentration was adjusted with 10% FBS growth 
medium in 96 well with cell density of 50 microliter. The cell 
suspension was stored in sterile reagent container for multi-
channel pipette. 
Treatment exposure: 
50 microliter of treatment sample was transferred in to each 
well of 96 well plate. Then cell suspension of 50 microliter 
was added to each well. Even cell distribution was observed 
at the bottom of the plate. A short spin was performed to the 
plate for 20 seconds. Three wells are incubated with above 
procedure with standard drug doxorubicin. 
Blank preparation: 
Three wells are filled with vehicle DMSO and cell suspension 
for untreated vehicle control, three wells are filled with 
DMSO only for background subtraction. 
Incubation: 
Plates are incubated at 37oC in a humidified incubator with 
5% CO until plates are recorded. 
Cell fixation and staining: 
To the treated cell lines 25 microliter of cold trichloroacetic 
acid 50%(w/v) is added to each well directly to medium 
supernatant, and plates are incubated at 4oC for 1 hour. The 
plates are washed four times with submerging the plate in a 
tub with slow running water. Gently tapping was done to 
remove the excess water in to a paper towel and air dried at 
room temperature. 
A 50 microliter 0.04% SRB solution was added to each well 
and incubated and kept at room temperature for 1 hour and 
quickly rinse the plates washed four times with 1%(v/v) 
acetic acid (200microliter) to remove unbound dye. Then 
plates air dried at room temperature and verified for the 
presence of air bubbles. 
Absorbance measurement: 
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50-100 microliter of tris-base solution of PH 10.5 was added 
to each well and shakes the plate in an orbital shaker 
incubator for 10 min to solubilise the protein bound dye. 
Then absorbance was measured at 510 nm in a micro plate 
reader. 
Calculations:  
Background absorbance was removed from all vessels 
Cell percentage growth = Absorbance sample/ Absorbance 
negative control X 100 
% Growth inhibition = 100 - % Cell growth.  
Growth inhibition was calculated of 50% was calculated as 
GI 50.  
TGI: Drug concentration resulting in total growth inhibition 
(TGI). 
LC50: Concentration of drug resulting in a 50 % reduction in 
the measured protein at the end of the drug treatment 
(concentration of drug causing lethality to 50 % of the cells 
as compared to that at the beginning) indicating a net loss of 
cells following treatment.  
  
Table 02 Experimental results of induvidual experiments 
  Experiment - 1 Experiment - 2 
SAMPLE ID 10-7M 10-6M 10-5M 10-4M 10-7M 10-6M 10-5M 10-4M 
PG-1A 100.0 100.0 100.0 -61.5 100.0 100.0 79.8 -57.0 
PG-1B 95.3 94.3 63.2 29.7 100.0 92.1 65.4 34.4 
PG-1C 100.0 100.0 97.3 46.6 100.0 100.0 77.2 39.5 
PG-1D 100.0 100.0 100.0 -36.5 100.0 100.0 74.9 -30.0 
PG-1E 100.0 100.0 100.0 -61.5 100.0 100.0 79.8 -57.0 
PG-1F 100.0 100.0 100.0 -61.2 100.0 100.0 74.1 -62.9 
RS-1A 100.0 100.0 100.0 21.9 100.0 100.0 89.5 19.9 
RS-1B 100.0 100.0 71.2 2.2 100.0 90.8 88.0 10.2 
RS-1C 100.0 100.0 100.0 -20.8 100.0 100.0 100.0 -40.9 
RS -1D 100.0 100.0 100.0 22.4 100.0 100.0 100.0 9.1 
RS -1E 100.0 100.0 100.0 52.5 100.0 100.0 100.0 41.6 
RS -1F 100.0 100.0 100.0 25.6 100.0 100.0 86.5 15.8 
OR-1A 100.0 100.0 100.0 3.5 100.0 72.4 12.7 -11.2 
OR-1B 100.0 100.0 100.0 61.2 100.0 92.4 77.8 54.6 
OR-1C 100.0 100.0 100.0 80.9 100.0 100.0 99.2 63.7 
OR-1D 100.0 100.0 100.0 25.6 100.0 100.0 86.5 15.8 
OR -1E 100.0 100.0 100.0 70.9 100.0 100.0 100.0 61.8 
OR -1F 100.0 100.0 100.0 39.8 100.0 100.0 100.0 14.5 
HQ-1A 100.0 100.0 100.0 30.1 100.0 100.0 100.0 25.1 
HQ-1B 100.0 100.0 100.0 -12.1 100.0 100.0 100.0 -37.6 
HQ-1C 100.0 100.0 100.0 15.3 100.0 100.0 100.0 12.2 
HQ-1D 100.0 100.0 100.0 46.9 100.0 100.0 99.5 43.8 
HQ -1E 100.0 100.0 100.0 70.9 100.0 100.0 100.0 61.8 
HQ -1F 100.0 100.0 100.0 -12.1 100.0 100.0 100.0 -37.6 
HL-1A 100.0 100.0 71.2 2.2 100.0 90.8 88.0 10.2 
HL-1B 100.0 100.0 100.0 21.9 100.0 100.0 89.5 19.9 
HL-1C 100.0 100.0 100.0 -61.2 100.0 100.0 74.1 -62.9 
HL-1D 100.0 100.0 100.0 -61.5 100.0 100.0 79.8 -57.0 
HL -1E 100.0 100.0 100.0 -36.5 100.0 100.0 74.9 -30.0 
HL -1F 100.0 100.0 97.3 46.6 100.0 100.0 77.2 39.5 
ADR 48.3 -44.4 -41.2 -55.0 -53.9 -65.2 -69.4 -73.5 
 
 
 Experiment - 3 Average Values 
SAMPLE ID 10-7M 10-6M 10-5M 10-4M 10-7M 10-6M 10-5M 10-4M 
PG-1A 100.0 89.6 79.1 -64.4 100.0 96.5 86.3 -61.0 
PG-1B 107.6 70.1 69.0 28.6 101.0 85.5 65.9 30.9 
PG-1C 100.0 89.3 75.3 34.6 100.0 96.4 83.3 40.0 
PG-1D 100.0 84.0 79.2 -37.7 100.0 94.7 84.7 -34.7 
PG-1E 100.0 89.6 79.1 -64.4 100.0 96.5 86.3 -61.0 
PG-1F 100.0 89.4 80.2 -63.3 100.0 96.5 84.8 -62.5 
RS-1A 100.0 100.0 86.1 15.8 100.0 100.0 91.9 19.2 
RS-1B 100.0 86.7 73.6 8.5 100.0 92.5 77.6 6.9 
RS-1C 100.0 100.0 100.0 -45.2 100.0 100.0 100.0 -35.6 
RS -1D 100.0 100.0 100.0 13.4 100.0 100.0 100.0 15.0 
RS -1E 100.0 100.0 100.0 42.2 100.0 100.0 100.0 45.4 
RS -1F 100.0 100.0 100.0 12.0 100.0 100.0 95.5 17.8 
OR-1A 100.0 100.0 17.5 -5.8 100.0 90.8 43.4 -4.5 
OR-1B 100.0 100.0 99.1 39.3 100.0 97.5 92.3 51.7 
OR-1C 100.0 100.0 100.0 49.8 100.0 100.0 99.7 64.8 
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OR-1D 100.0 100.0 100.0 12.0 100.0 100.0 95.5 17.8 
OR -1E 100.0 100.0 100.0 51.8 100.0 100.0 100.0 61.5 
OR -1F 100.0 100.0 100.0 21.5 100.0 100.0 100.0 25.3 
HQ-1A 100.0 100.0 100.0 35.1 100.0 100.0 100.0 30.1 
HQ-1B 100.0 100.0 100.0 -40.3 100.0 100.0 100.0 -30.0 
HQ-1C 100.0 100.0 100.0 13.1 100.0 100.0 100.0 13.5 
HQ-1D 100.0 100.0 100.0 41.0 100.0 100.0 99.8 43.9 
HQ -1E 100.0 100.0 100.0 51.8 100.0 100.0 100.0 61.5 
HQ -1F 100.0 100.0 100.0 -40.3 100.0 100.0 100.0 -30.0 
HL-1A 100.0 86.7 73.6 8.5 100.0 92.5 77.6 6.9 
HL-1B 100.0 100.0 86.1 15.8 100.0 100.0 91.9 19.2 
HL-1C 100.0 89.4 80.2 -63.3 100.0 96.5 84.8 -62.5 
HL-1D 100.0 89.6 79.1 -64.4 100.0 96.5 86.3 -61.0 
HL -1E 100.0 84.0 79.2 -37.7 100.0 94.7 84.7 -34.7 
HL -1F 100.0 89.3 75.3 34.0 100.0 96.4 83.3 40.0 
ADR -66.5 -78.0 -82.1 -83.6 -24.0 -62.5 -64.2 -70.7 
 
Table 3 Anti-cancer activity with molar drug concentration 
G361 Molar drug concentration 
  LC 50 TGI GI50 
PG-1A >10-4  3.2*10-5  2.02*10-6 
PG-1B >10-4 >10-4  2.8*10-6 
PG-1C >10-4  >10-4  3.8*10-5 
PG-1D >10-4  3.7*10-5  2.2*10-6 
PG-1E >10-4  3.2*10-5  2.04*10-6 
PG-1F >10-4  3.2*10-5  2.02*10-6 
RS-1A >10-4  >10-4  3.2*10-5 
RS-1B >10-4 >10-4  2.6*10-6 
RS-1C >10-4  >10-4  2.3*10-6 
RS -1D >10-4 >10-4  3.2*10-5 
RS -1E >10-4  >10-4   >10-4 
RS -1F >10-4  >10-4  3.2*10-5 
OR-1A >10-4  3.7*10-5 2.1*10-6 
OR-1B >10-4  >10-4  >10-4 
OR-1C >10-4  >10-4  >10-4 
OR-1D >10-4 >10-4  3.2*10-5 
OR -1E >10-4  >10-4 >10-4 
OR -1F >10-4 >10-4  3.6*10-5 
HQ-1A >10-4  >10-4  3.9*10-5 
HQ-1B >10-4  >10-4  2.4*10-6 
HQ-1C >10-4  >10-4 3.2*10-5 
HQ-1D >10-4  >10-4  >10-4 
HQ -1E >10-4  >10-4  >10-4 
HQ -1F >10-4 >10-4  2.4*10-6 
HL-1A >10-4 >10-4 2.6*10-6 
HL-1B >10-4 >10-4 3.2*10-5 
HL-1C >10-4  3.2*10-5  2.02*10-6 
HL-1D >10-4  3.2*10-5  2.04*10-6 
HL -1E >10-4  3.7*10-5  2.2*10-6 
HL -1F >10-4  >10-4  3.8*10-5 
ADR  1.7*10-7  <10-7  <10-7 
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Fig 1 Anti-cancer results group-I 
 
 
Fig 2 Anti-cancer results group-II 
 
Fig 3 Anti-cancer results group-III 
 
 
Fig 4 Anti cancer results group-IV 
 
CONCLUSION 
The synthesized molecules had been diluted at four different 
concentrations and Sulfordamine B assay method was opted 
for screening of anti-cancer activity. The results were 
compared with doxorubicin as standard drug at similar 
concentrations. The compounds exhibited good results. 
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